过氧化物酶体增殖物激活受体
过氧化物酶体
胰岛素抵抗
医学
内分泌学
内科学
糖尿病性心肌病
脂肪酸代谢
β氧化
脂肪酸
脂质代谢
甘油三酯
碳水化合物代谢
受体
新陈代谢
胰岛素
心肌病
生物
生物化学
心力衰竭
胆固醇
作者
David Montaigne,Laura Butruille,Bart Staels
标识
DOI:10.1038/s41569-021-00569-6
摘要
Peroxisome proliferator-activated receptor-α (PPARα), PPARδ and PPARγ are transcription factors that regulate gene expression following ligand activation. PPARα increases cellular fatty acid uptake, esterification and trafficking, and regulates lipoprotein metabolism genes. PPARδ stimulates lipid and glucose utilization by increasing mitochondrial function and fatty acid desaturation pathways. By contrast, PPARγ promotes fatty acid uptake, triglyceride formation and storage in lipid droplets, thereby increasing insulin sensitivity and glucose metabolism. PPARs also exert antiatherogenic and anti-inflammatory effects on the vascular wall and immune cells. Clinically, PPARγ activation by glitazones and PPARα activation by fibrates reduce insulin resistance and dyslipidaemia, respectively. PPARs are also physiological master switches in the heart, steering cardiac energy metabolism in cardiomyocytes, thereby affecting pathological heart failure and diabetic cardiomyopathy. Novel PPAR agonists in clinical development are providing new opportunities in the management of metabolic and cardiovascular diseases. Novel peroxisome proliferator-activated receptor (PPAR) agonists are providing new opportunities in the management of metabolic and cardiovascular diseases. In this Review, Staels and colleagues discuss the physiological regulation and actions of the PPAR family and their modulation of the atherogenic lipid profile, atherosclerosis and cardiac remodelling.
科研通智能强力驱动
Strongly Powered by AbleSci AI